Does USTEKINUMAB Cause Hepatocellular carcinoma? 60 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 60 reports of Hepatocellular carcinoma have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.1% of all adverse event reports for USTEKINUMAB.
60
Reports of Hepatocellular carcinoma with USTEKINUMAB
0.1%
of all USTEKINUMAB reports
6
Deaths
35
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From USTEKINUMAB?
Of the 60 reports, 6 (10.0%) resulted in death, 35 (58.3%) required hospitalization, and 14 (23.3%) were considered life-threatening.
Is Hepatocellular carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 60 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
Which USTEKINUMAB Alternatives Have Lower Hepatocellular carcinoma Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE